AAV-mediated gene therapy in a model of SLC13A5 citrate transporter disorder rescues epileptic and metabolic phenotypes
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci197503 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Lauren E Bailey und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Alzheimer's and Neurodegenerative Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Dependovirus, Symporters, Epilepsy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, TESS Research Foundation, Taysha Gene Therapies.
Abstract (Originalsprache)
SLC13A5 citrate transporter disorder is a rare epileptic encephalopathy caused by loss-of-function pathogenic variants in the SLC13A5 gene. Loss of sodium/citrate cotransporter (NaCT) function causes a severe early-life epilepsy resulting in lifelong developmental disabilities and increased extracellular citrate. Current antiseizure medications may reduce seizure frequency, yet more targeted treatments are needed to address the epileptic and neurodevelopmental SLC13A5 phenotype. We performed preclinical studies in SLC13A5-deficient (KO) mice evaluating phenotype rescue with adeno-associated virus (AAV) vector carrying a functional copy of the human SLC13A5 gene (AAV9/SLC13A5). Cerebrospinal fluid delivery of AAV9/SLC13A5 decreased extracellular citrate levels, normalized electrophysiologic and sleep architecture abnormalities, and restored resistance to chemically induced seizures and death. Treatment benefits were achieved with administration during early brain development and in young adult mice, indicating therapeutic efficacy across developmental and postdevelopmental stages. Comparison of delivery routes in young adult KO mice showed that higher brain targeting achieved with intra–cisterna magna delivery resulted in greater treatment benefit as compared with intrathecal lumbar puncture delivery. Together, these results support further development of AAV9/SLC13A5 for treating SLC13A5 citrate transporter disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Alzheimer's and Neurodegenerative Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Graduate School of Biomedical Sciences, University of Texas Southwestern Medical School, Dallas, Texas, USA.
- Department of Health Data Science and Biostatistics, Peter O'Donnell Jr. School of Public Health, and.
- Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Förderung
- NIDDK NIH HHS
- TESS Research Foundation
- Taysha Gene Therapies
Zitieren
APA
Bailey, L. E., Adams, R. M., Schackmuth, M. K., Garza, I. T., Knight, K., Holmes, S. K., Eller, M. M., Lee, M., & Bailey, R. M. (2026). AAV-mediated gene therapy in a model of SLC13A5 citrate transporter disorder rescues epileptic and metabolic phenotypes. Journal of Clinical Investigation. https://doi.org/10.1172/jci197503
Vancouver
Bailey LE, Adams RM, Schackmuth MK, Garza IT, Knight K, Holmes SK, et al. AAV-mediated gene therapy in a model of SLC13A5 citrate transporter disorder rescues epileptic and metabolic phenotypes. Journal of Clinical Investigation. 2026. doi:10.1172/jci197503
BibTeX
@article{Bailey2026,
author = {Bailey, Lauren E and Adams, Raegan M and Schackmuth, Morgan K and Garza, Irvin T and Knight, Krishanna and Holmes, Sydni K and Eller, Meghan M and Lee, MinJae and Bailey, Rachel M},
title = {AAV-mediated gene therapy in a model of SLC13A5 citrate transporter disorder rescues epileptic and metabolic phenotypes},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci197503}
}
EUVIMED